Format

Send to

Choose Destination
Eur J Cancer. 2014 Jul;50(10):1717-1721. doi: 10.1016/j.ejca.2014.03.001. Epub 2014 Apr 10.

Afatinib use in non-small cell lung cancer previously sensitive to epidermal growth factor receptor inhibitors: the United Kingdom Named Patient Programme.

Author information

1
Academic Unit of Clinical Oncology, Weston Park Hospital, Sheffield S10 2SJ, United Kingdom.
2
Southampton NIHR Experimental Cancer Medicine Center and Southampton University Hospitals NHS Foundation, Southampton SO16 6YD, United Kingdom.
3
Royal Marsden Hospital, London SW3 6JJ, United Kingdom.
4
Guy's and St. Thomas' NHS Foundation Trust, London SE1 9RT, United Kingdom.
5
Royal Devon and Exeter NHS Foundation Trust, Exeter EX2 5DW, United Kingdom.
6
Royal Bournemouth Hospital, Bournemouth BH7 7DW, United Kingdom.
7
Hull and East Yorkshire Hospitals NHS Trust, Hull HU16 5JQ, United Kingdom.
8
Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester M20 4BX, United Kingdom.
9
Harrogate and District NHS Foundation Trust, Harrogate HG2 7SX, United Kingdom.
10
Beatson West of Scotland Cancer Centre, Glasgow G12 0YN, United Kingdom.
11
Aberdeen Royal Infirmary, Aberdeen AB25 2ZN, United Kingdom.
12
Velindre Cancer Centre, Cardiff CF14 2TL, United Kingdom.
13
United Lincolnshire Hospitals NHS Trust, Lincoln LN2 5QY, United Kingdom.
14
Newcastle upon Tyne NHS Foundation Trust, Newcastle NE7 7DN, United Kingdom.
15
University College London Hospitals NHS Foundation Trust, London NW1 2PG, United Kingdom.
16
Academic Unit of Clinical Oncology, Weston Park Hospital, Sheffield S10 2SJ, United Kingdom. Electronic address: s.danson@sheffield.ac.uk.

Abstract

INTRODUCTION:

Afatinib prolongs progression-free survival (PFS) in patients with non-small cell lung cancer (NSCLC) who were previously sensitive to erlotinib or gefitinib. This study investigated experience of afatinib under a Named Patient Use (NPU) programme.

PATIENTS AND METHODS:

Retrospective data for 63 patients were collected, including demographics, dose, toxicity and clinical efficacy.

RESULTS:

Response rate and median PFS were 14.3% and 2.6months, respectively. Diarrhoea and rash were the most common toxicities; 46% of patients required a dose reduction and 41% had a dose delay.

CONCLUSIONS:

Efficacy and safety in the NPU programme are consistent with the LUX-Lung 1 trial.

KEYWORDS:

Afatinib; EGFR; Non-small cell lung cancer

PMID:
24726055
DOI:
10.1016/j.ejca.2014.03.001
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center